$BTCY
BIOTRICITY INC. Stock $btcy

$btcy Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222023040 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$2.381M	$2.056M	$2.149M
YoY Change	31.76%	16.55%	81.02%
Cost Of Revenue	$1.101M	$830.9K	$708.1K
YoY Change	63.69%	39.88%	51.21%
Gross Profit	$1.280M	$1.225M	$1.441M
YoY Change	12.84%	4.7%	100.44%
Gross Profit Margin	53.76%	59.59%	67.05%
Selling, General & Admin	$4.859M	$4.850M	$5.894M
YoY Change	-11.98%	46.16%	90.98%
% of Gross Profit	379.51%	395.84%	409.12%
Research & Development	$828.9K	$821.2K	$629.5K
YoY Change	32.49%	39.42%	14.13%
% of Gross Profit	64.75%	67.03%	43.69%
Depreciation & Amortization	$1.489K	$1.489K	$1.490K
YoY Change
% of Gross Profit	0.12%	0.12%	0.1%
Operating Expenses	$5.713M	$5.702M	$6.523M
YoY Change	-7.05%	36.66%	79.33%
Operating Profit	-$4.433M	-$4.477M	-$5.083M
YoY Change	-11.55%	49.11%	74.13%
Interest Expense	-$76.07K	-$81.48K	-$482.4K
YoY Change	-98.57%	-96.87%	-76.87%
% of Operating Profit
Other Income/Expense, Net	$2.891K		$1.109M
YoY Change	-100.69%		-405.22%
Pretax Income	-$4.693M	-$4.776M	-$5.612M
YoY Change	-56.36%	-15.56%	2.56%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$4.693M	-$4.776M	-$5.612M
YoY Change	-56.36%	-15.56%	2.56%
Net Earnings / Revenue	-197.05%	-232.3%	-261.17%
Basic Earnings Per Share	-$0.09	-$0.10
Diluted Earnings Per Share	-$90.21K	-$92.85K	-$111.0K
COMMON SHARES
Basic Shares Outstanding	50.43M shares	51.44M shares
Diluted Shares Outstanding	8.643M shares	51.44M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.498M	$7.208M	$12.07M
YoY Change	-78.64%	3475.56%	448.11%
Cash & Equivalents	$2.498M	$7.208M	$12.07M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$1.854M	$1.431M	$842.9K
Prepaid Expenses
Receivables	$2.009M	$1.827M	$2.007M
Other Receivables	$391.6K	$380.6K	$406.3K
Total Short-Term Assets	$6.752M	$10.85M	$15.32M
YoY Change	-51.59%	295.19%	254.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.48K	$25.97K	$27.46K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.301M	$1.303M	$1.355M
YoY Change	22144.91%	5648.3%	1063.45%
TOTAL ASSETS
Total Short-Term Assets	$6.752M	$10.85M	$15.32M
Total Long-Term Assets	$1.301M	$1.303M	$1.355M
Total Assets	$8.053M	$12.15M	$16.68M
YoY Change	-42.28%	339.05%	275.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.227M	$1.458M	$1.159M
YoY Change	-24.4%	13.64%	11.34%
Accrued Expenses	$1.409M	$1.243M	$1.436M
YoY Change	31.9%	-25.91%	-2.87%
Deferred Revenue
YoY Change
Short-Term Debt	$1.138M	$1.238M	$1.540M
YoY Change	-37.85%	-77.87%	-64.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.389M	$4.577M	$4.867M
YoY Change	-15.83%	-62.75%	-53.61%
LONG-TERM LIABILITIES
Long-Term Debt	$12.58M	$12.53M	$12.48M
YoY Change	1345.15%	1339.31%	3265.72%
Other Long-Term Liabilities	$1.704M	$1.599M	$1.472M
YoY Change	1298.4%	674.31%	259.09%
Total Long-Term Liabilities	$14.29M	$14.13M	$13.96M
YoY Change	1339.41%	1211.83%	1687.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.389M	$4.577M	$4.867M
Total Long-Term Liabilities	$14.29M	$14.13M	$13.96M
Total Liabilities	$18.68M	$18.71M	$18.82M
YoY Change	200.89%	39.97%	67.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$103.0M	-$98.06M	-$93.04M
YoY Change			48.11%
Common Stock	$51.90K	$51.69K	$51.28K
YoY Change			31.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$10.62M	-$6.560M	-$2.145M
YoY Change
Total Liabilities & Shareholders Equity	$8.053M	$12.15M	$16.68M
YoY Change	-42.28%	339.05%	275.8%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$4.693M	-$4.776M	-$5.612M
YoY Change	-56.36%	-15.56%	2.56%
Depreciation, Depletion And Amortization	$1.489K	$1.489K	$1.490K
YoY Change
Cash From Operating Activities	-$4.451M	-$4.039M	-$4.755M
YoY Change	37.4%	50.65%	32.84%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-272.8K	-$833.2K	155.2K
YoY Change	-101.84%	-243.39%	-94.0%
NET CHANGE
Cash From Operating Activities	-4.451M	-$4.039M	-4.755M
Cash From Investing Activities			0.000
Cash From Financing Activities	-272.8K	-$833.2K	155.2K
Net Change In Cash	-4.724M	-$4.859M	-4.600M
YoY Change	-140.81%	142.95%	363.05%
FREE CASH FLOW
Cash From Operating Activities	-$4.451M	-$4.039M	-$4.755M
Capital Expenditures			$0.00
Free Cash Flow			-$4.755M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Document Type DocumentType	10-Q
CY2022Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q2	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q2	dei	Entity File Number EntityFileNumber	000-56074
CY2022Q2	dei	Entity Registrant Name EntityRegistrantName	BIOTRICITY INC.
CY2022Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0983531
CY2022Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	203 Redwood Shores Parkway
CY2022Q2	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2022Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001630113
CY2022Q2	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2022Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q2	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent		usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2021Q2	us-gaap	Depreciation Depreciation		usd
CY2021Q2	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock		usd
CY2022Q2	BTCY	Federal Guaranteed Loans FederalGuaranteedLoans		usd
CY2022Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022Q2	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions		usd
CY2022Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2022Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2022Q2	dei	City Area Code CityAreaCode	(650)
CY2022Q2	dei	Local Phone Number LocalPhoneNumber	832-1626
CY2022Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q2	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q2	dei	Trading Symbol TradingSymbol	BTCY
CY2022Q2	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50431245	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7207974	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12066929	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1826920	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2006678	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1431054	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	842924	usd
CY2022Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	380592	usd
CY2022Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	406280	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	10846540	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	15322811	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	85000	usd
CY2022Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	85000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25970	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27459	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1192169	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1242700	usd
CY2022Q2	us-gaap	Assets Assets	12149679	usd
CY2022Q1	us-gaap	Assets Assets	16677970	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2701077	usd
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2595747	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1238000	usd
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1540000	usd
CY2022Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	419332	usd
CY2022Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	520747	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	219033	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	210320	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4577442	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4866814	usd
CY2022Q2	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	870800	usd
CY2022Q1	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	870800	usd
CY2022Q2	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	11662742	usd
CY2022Q1	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	11612672	usd
CY2022Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	537318	usd
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	352402	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1061795	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1120018	usd
CY2022Q2	us-gaap	Liabilities Liabilities	18710097	usd
CY2022Q1	us-gaap	Liabilities Liabilities	18822706	usd
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	7500	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	1170081	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4881003	usd
CY2022Q2	BTCY	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	77414	usd
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50219034	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49810322	shares
CY2022Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1466718	shares
CY2022Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1466718	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	51686	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	51277	usd
CY2022Q2	BTCY	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	95515	shares
CY2022Q1	BTCY	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	123817	shares
CY2022Q2	BTCY	Shares To Be Issued SharesToBeIssued	72299	usd
CY2022Q1	BTCY	Shares To Be Issued SharesToBeIssued	102299	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	91912772	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	91507478	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-535652	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-768656	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98061531	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93037142	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6560418	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2144736	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12149679	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16677970	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2056052	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1764110	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	830923	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	594029	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	1225129	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3583600	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	821176	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	588997	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	5702179	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	4172597	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8782	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-50908	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-28215	usd
CY2022Q2	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-50070	usd
CY2021Q2	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2335167	usd
CY2021Q2	BTCY	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	151897	usd
CY2022Q2	us-gaap	Accretion Expense AccretionExpense	50070	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-198224	usd
CY2021Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-298983	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4776252	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5656099	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4776252	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5656099	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	248137	usd
CY2021Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	241264	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5024389	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5897363	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	233004	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	6560	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4791385	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5890803	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.098
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.151
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51440944	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39095637	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2144736	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	457026	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	285427	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	7500	usd
CY2022Q2	BTCY	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	-30000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	77414	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	149190	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	233004	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4776252	usd
CY2022Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	248137	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6560418	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-6833164	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1670262	usd
CY2021Q2	BTCY	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	146250	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	151897	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	155851	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	6560	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5656099	usd
CY2021Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	241264	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-10599707	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-4776252	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-5656099	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	149190	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	155851	usd
CY2021Q2	us-gaap	Accretion Expense AccretionExpense	2335167	usd
CY2022Q2	BTCY	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-198224	usd
CY2021Q2	BTCY	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-298983	usd
CY2022Q2	BTCY	Loss Upon Convertible Promissory Notes Conversion LossUponConvertiblePromissoryNotesConversion	50908	usd
CY2021Q2	BTCY	Loss Upon Convertible Promissory Notes Conversion LossUponConvertiblePromissoryNotesConversion	28213	usd
CY2022Q2	us-gaap	Depreciation Depreciation	1489	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-179758	usd
CY2021Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	401818	usd
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	588130	usd
CY2021Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-92694	usd
CY2022Q2	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	4312	usd
CY2021Q2	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	86221	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	614747	usd
CY2021Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	399937	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4039394	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2681396	usd
CY2022Q2	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock	328904	usd
CY2022Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12500	usd
CY2021Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	146250	usd
CY2021Q2	BTCY	Federal Guaranteed Loans FederalGuaranteedLoans	499900	usd
CY2021Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	139780	usd
CY2022Q2	BTCY	Repayments Of Preferred Stock Dividend RepaymentsOfPreferredStockDividend	516817	usd
CY2021Q2	BTCY	Repayments Of Preferred Stock Dividend RepaymentsOfPreferredStockDividend	204842	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-833221	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	581088	usd
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13660	usd
CY2021Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	100334	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4858955	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1999974	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12066929	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2201562	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7207974	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	201588	usd
CY2022Q2	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_z4tQ4YveBg0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_823_zLspQ3i42bW">NATURE OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98061531	usd
CY2022Q2	BTCY	Working Capital Deficit WorkingCapitalDeficit	6269098	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14545805	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	11756563	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2056052	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1764110	usd
CY2022Q2	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zWYqY9Um02ai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86C_zBmOvad1IwDi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Significant accounting estimates and assumptions</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, structured notes, convertible debt and conversion liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of stock options</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of warrants</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of derivative liabilities</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used valuation models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Functional currency</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Useful life of property and equipment</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Provisions</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contingencies</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Inventory obsolescence</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income and other taxes</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated statements of financial position, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company’s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company’s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Incremental borrowing rate for lease</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	302000	usd
CY2022Q2	BTCY	Convertible Promissory Notes And Short Term Loans ConvertiblePromissoryNotesAndShortTermLoans	1238000	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	12000000	usd
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-12-21
CY2022Q2	BTCY	Scheduleofpropertyandequipmentestimatedusefullivestabletextblock SCHEDULEOFPROPERTYANDEQUIPMENTESTIMATEDUSEFULLIVESTABLETEXTBLOCK	<p id="xdx_899_ecustom--SCHEDULEOFPROPERTYANDEQUIPMENTESTIMATEDUSEFULLIVESTABLETEXTBLOCK_z0czSgHehtjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zz7tFORCOy19" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dm_c20220401__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zPbsbJb2ziM8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvement</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dm_c20220401__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LeaseholdImprovementMember_ztgjHuzbnJu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/>
CY2021Q4	us-gaap	Debt Instrument Payment Terms DebtInstrumentPaymentTerms	Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances
CY2021Q4	us-gaap	Debt Instrument Date Of First Required Payment1 DebtInstrumentDateOfFirstRequiredPayment1	2022-02-15
CY2021Q4	BTCY	Origination Fee Amount OriginationFeeAmount	120000	usd
CY2021Q4	BTCY	Exit Fees ExitFees	600000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	193437	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	48484	usd
CY2021Q4	BTCY	Debt Instrument Fees And Other Expenses DebtInstrumentFeesAndOtherExpenses	144953	usd
CY2021Q4	us-gaap	Proceeds From Loans ProceedsFromLoans	12000000	usd
CY2022Q2	BTCY	Accounts Payable And Deferred Revenue Current AccountsPayableAndDeferredRevenueCurrent	1457901	usd
CY2022Q1	BTCY	Accounts Payable And Deferred Revenue Current AccountsPayableAndDeferredRevenueCurrent	1159477	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1243176	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1436270	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2701077	usd
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2595747	usd
CY2022Q2	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	20300	usd
CY2022Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2851	usd
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.06
CY2022Q1	BTCY	Convertible Promissory Notes And Short Term Loans ConvertiblePromissoryNotesAndShortTermLoans	1540000	usd
CY2021Q4	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1574068	usd
CY2021Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1042149	usd
CY2022Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	50070	usd
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	352402	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-195521	usd
CY2022Q2	BTCY	Reduction Due To Preferred Shares Redeemed ReductionDueToPreferredSharesRedeemed	-10605	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	537318	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	520747	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	419332	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50219034	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49810322	shares
CY2022Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1466718	shares
CY2022Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1466718	shares
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	250000	shares
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1414449	usd
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	658355	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	97500	shares
CY2022Q1	BTCY	Class Of Warrant Or Right Cashless Warrant Exercise ClassOfWarrantOrRightCashlessWarrantExercise	446370	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	10843202	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	449174	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1459918	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	643534	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	9577644	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	1563980	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	11792	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	53827	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	8055698	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.76
CY2022	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
CY2021	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
CY2020	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.114	pure
CY2022Q1	BTCY	Operating Lease Right Of Use Asset Initial Recognition OperatingLeaseRightOfUseAssetInitialRecognition	1242700	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	50531	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1192169	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1330338	usd
CY2022Q2	BTCY	Operating Lease Repayment And Interest Accretion OperatingLeaseRepaymentAndInterestAccretion	-49510	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1280828	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	219033	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1061795	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1630941	usd
CY2022Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	12928	usd
CY2022Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	16839	usd
CY2022Q2	us-gaap	Depreciation Depreciation	1489	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29767	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29767	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2308	usd
CY2022Q2	us-gaap	Depreciation Depreciation	1489	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3797	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27459	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25970	usd

Files In Submission

Name	View Source	Status
0001493152-22-023040-index-headers.html	Edgar Link	pending
0001493152-22-023040-index.html	Edgar Link	pending
0001493152-22-023040.txt	Edgar Link	pending
0001493152-22-023040-xbrl.zip	Edgar Link	pending
btcy-20220630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
btcy-20220630_cal.xml	Edgar Link	unprocessable
btcy-20220630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
btcy-20220630_lab.xml	Edgar Link	unprocessable
btcy-20220630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTCY
BIOTRICITY INC. Stock $btcy

2022 Q3 Form 10-Q Financial Statement

#000149315222023040 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCY BIOTRICITY INC. Stock $btcy

2022 Q3 Form 10-Q Financial Statement

#000149315222023040 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCY
BIOTRICITY INC. Stock $btcy